Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Klopfleisch, Robert ^a   Lenze, Dido ^b   Hummel, Michael ^b   Gruber, Achim D ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BONE MORPHOGENETIC PROTEIN 6; CELL CYCLE PROTEIN; EPHRIN RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; G PROTEIN COUPLED RECEPTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MATURATION PROMOTING FACTOR; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; PROTEIN TYROSINE KINASE INHIBITOR; RAD51 PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; MESSENGER RNA; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DOG; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; IMMUNOHISTOCHEMISTRY; METASTASIS POTENTIAL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN FOLDING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; BREAST TUMOR; CELL CYCLE; DISEASE COURSE; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; LYMPH NODE METASTASIS; METABOLISM; METHODOLOGY; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE; CELL DIFFERENTIATION; DISEASE PROGRESSION; DOGS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, ANIMAL; RNA, MESSENGER;

EID: 78049523510     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-618     Document Type: Article

References (52)

1. Benjamin SA, Lee AC, Saunders WJ. Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in beagles. Vet Pathol 1999, 36(5):423-436. 10.1354/vp.36-5-423, 10490210.
2. Kitchell BE, Loar AS. Diseases of the mammary glands. Handbook of Small Animal Practice 1997, 615-625. WB Saunders, Philadelphia, Morgan RV, 3.
3. Misdorp W. Tumors of the mammary gland. Tumours in Domestic Animals 2002, 575-606. Iowa State Press, Iowa, Meuten DJ, 4.
4. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Archives of pathology & laboratory medicine 2000, 124(7):966-978.
5. Misdorp W, Hart AA. Prognostic factors in canine mammary cancer. J Natl Cancer Inst 1976, 56(4):779-786.
6. Misdorp W, Hart AA. Canine mammary cancer. II. Therapy and causes of death. The Journal of small animal practice 1979, 20(7):395-404. 10.1111/j.1748-5827.1979.tb06744.x, 470351.
7. Setoguchi A, Sakai T, Okuda M, Minehata K, Yazawa M, Ishizaka T, Watari T, Nishimura R, Sasaki N, Hasegawa A, et al. Aberrations of the p53 tumor suppressor gene in various tumors in dogs. Am J Vet Res 2001, 62(3):433-439. 10.2460/ajvr.2001.62.433, 11277210.
8. Nieto A, Perez-Alenza MD, Del Castillo N, Tabanera E, Castano M, Pena L. BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables. J Comp Pathol 2003, 128(4):260-268. 10.1053/jcpa.2002.0631, 12834609.
9. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001, 3(9):785-792. 10.1038/ncb0901-785, 2952547, 11533657.
10. Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer 2008, 8:394. 10.1186/1471-2407-8-394, 2642844, 19116006.
11. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 2008, 108(2):191-201. 10.1007/s10549-007-9596-6, 18297396.
12. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, Van't Veer LJ. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005, 65(20):9155-9158. 10.1158/0008-5472.CAN-05-2553, 16230372.
13. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536. 10.1038/415530a, 11823860.
14. Rao NA, van Wolferen ME, Gracanin A, Bhatti SF, Krol M, Holstege FC, Mol JA. Gene expression profiles of progestin-induced canine mammary hyperplasia and spontaneous mammary tumors. J Physiol Pharmacol 2009, 60(Suppl 1):73-84.
15. Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, Palombo F, Viti V, Mesiti G, Zappulli V, et al. Comparative expression pathway analysis of human and canine mammary tumors. BMC genomics 2009, 10:135. 10.1186/1471-2164-10-135, 2670324, 19327144.
16. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, et al. The dog as a cancer model. Nat Biotechnol 2006, 24(9):1065-1066. 10.1038/nbt0906-1065b, 16964204.
17. Klopfleisch R, Klose P, Gruber AD. The combined expression pattern of BMP2, LTBP4, and DERL1 discriminates malignant from benign canine mammary tumors. Vet Pathol 2010, 47(3):446-454. 10.1177/0300985810363904, 20375427.
18. Sassi F, Benazzi C, Castellani G, Sarli G. Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Vet Res 2010, 6:5. 10.1186/1746-6148-6-5, 2837647, 20109214.
19. Misdorp W, Else RW, Hellmén E, Lipscomb TP. Histological classification of mammary tumors of the dog and the cat. 1999, 7. Washington: Armed Forces Institute of Pathology.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
21. Klopfleisch R, Henning H, Costa da A, Klose P, Gruber AD. Insulin receptor is expressed in normal canine mammary gland and benign adenomas but decreased in metastatic canine mammary carcinomas similar to human breast cancer. Vet Comp Oncol 2010,
22. Klopfleisch R, Gruber AD. Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas. Vet Pathol 2009, 46(3):416-422. 10.1354/vp.08-VP-0212-K-FL, 19176491.
23. Klopfleisch R, Klose P, da Costa A, Brunnberg L, Gruber AD. HEPACAM1 and 2 are differentially regulated in canine mammary adenomas and carcinomas and its lymph node metastases. BMC Vet Res 2010, 6:15. 10.1186/1746-6148-6-15, 2842258, 20226097.
24. Klopfleisch R, Schutze M, Gruber AD. Downregulation of transforming growth factor beta (TGFbeta) and latent TGFbeta binding protein (LTBP)-4 expression in late stage canine mammary tumours. The Veterinary Journal 2009,
25. Klopfleisch R, Gruber AD. Derlin-1 and stanniocalcin-1 are differentially regulated in metastasizing canine mammary adenocarcinomas. J Comp Pathol 2009, 141(2-3):113-120. 10.1016/j.jcpa.2008.09.010, 19515379.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
27. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3(7):RESEARCH0034. 10.1186/gb-2002-3-7-research0034, 126239, 12184808.
28. Etschmann B, Wilcken B, Stoevesand K, von der Schulenburg A, Sterner-Kock A. Selection of reference genes for quantitative real-time PCR analysis in canine mammary tumors using the GeNorm algorithm. Vet Pathol 2006, 43(6):934-942. 10.1354/vp.43-6-934, 17099150.
29. Cardin S, Libby E, Pelletier P, Le Bouter S, Shiroshita-Takeshita A, Le Meur N, Leger J, Demolombe S, Ponton A, Glass L, et al. Contrasting gene expression profiles in two canine models of atrial fibrillation. Circ Res 2007, 100(3):425-433. 10.1161/01.RES.0000258428.09589.1a, 17234964.
30. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4(1):44-57. 10.1038/nprot.2008.211, 19131956.
31. Hu Y, Hines LM, Weng H, Zuo D, Rivera M, Richardson A, LaBaer J. Analysis of genomic and proteomic data using advanced literature mining. J Proteome Res 2003, 2(4):405-412. 10.1021/pr0340227, 12938930.
32. Salomonis N, Hanspers K, Zambon AC, Vranizan K, Lawlor SC, Dahlquist KD, Doniger SW, Stuart J, Conklin BR, Pico AR. GenMAPP 2: new features and resources for pathway analysis. BMC bioinformatics 2007, 8:217. 10.1186/1471-2105-8-217, 1924866, 17588266.
33. Klopfleisch R, Gruber AD. Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Res Vet Sci 2009, 87(1):91-96. 10.1016/j.rvsc.2008.12.010, 19185891.
34. Klopfleisch R, Schutze M, Gruber AD. Loss of p27 expression in canine mammary tumors and their metastases. Res Vet Sci 2010, 88(2):300-303. 10.1016/j.rvsc.2009.08.007, 19748645.
35. Benson JR. Role of transforming growth factor beta in breast carcinogenesis. The lancet oncology 2004, 5(4):229-239. 10.1016/S1470-2045(04)01426-3, 15050954.
36. Schwertfeger KL. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Current drug targets 2009, 10(7):632-644.
37. Muraoka-Cook RS, Feng SM, Strunk KE, Earp HS. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. Journal of mammary gland biology and neoplasia 2008, 13(2):235-246. 10.1007/s10911-008-9080-x, 18437540.
38. Lah TT, Kalman E, Najjar D, Gorodetsky E, Brennan P, Somers R, Daskal I. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis. Human pathology 2000, 31(2):149-160. 10.1016/S0046-8177(00)80214-2, 10685628.
39. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Trinh XB, Van Marck EA, Dirix LY, Vermeulen PB. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 2009, 125(6):1494-1496. 10.1002/ijc.24524, 19536843.
40. Nakopoulou L, Panayotopoulou EG, Giannopoulou I, Alexandrou P, Katsarou S, Athanassiadou P, Keramopoulos A. Stromelysin-3 protein expression in invasive breast cancer: relation to proliferation, cell survival and patients' outcome. Mod Pathol 2002, 15(11):1154-1161. 10.1097/01.MP.0000037317.84782.CD, 12429794.
41. Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, Brizzi MF, Sacchi A, Soddu S, Blandino G, et al. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. Cancer Res 2009, 69(14):5978-5986. 10.1158/0008-5472.CAN-09-0244, 19567674.
42. Moh MC, Zhang T, Lee LH, Shen S. Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells. Carcinogenesis 2008, 29(12):2298-2305. 10.1093/carcin/bgn226, 18845560.
43. Yoon KJ, Phelps DA, Bush RA, Remack JS, Billups CA, Khoury JD. ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. PloS one 2008, 3(11):e3629. 10.1371/journal.pone.0003629, 2575377, 18978946.
44. Christgen M, Christgen H, Heil C, Krech T, Langer F, Kreipe H, Lehmann U. Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer. Cancer science 2009, 100(9):1767-1771. 10.1111/j.1349-7006.2009.01231.x, 19549254.
45. Hirschfeld M, zur Hausen A, Bettendorf H, Jager M, Stickeler E. Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res 2009, 69(5):2082-2090. 10.1158/0008-5472.CAN-08-1997, 19244129.
46. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, Klagsbrun M. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci USA 2000, 97(6):2573-2578. 10.1073/pnas.040337597, 15970, 10688880.
47. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-679.
48. Gama A, Paredes J, Gartner F, Alves A, Schmitt F. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival. Vet J 2008, 177(1):45-53. 10.1016/j.tvjl.2007.05.024, 17631398.
49. De Matos AJ, Lopes CC, Faustino AM, Carvalheira JG, Rutteman GR, Gartner Mde F. E-cadherin, beta-catenin, invasion and lymph node metastases in canine malignant mammary tumours. Apmis 2007, 115(4):327-334. 10.1111/j.1600-0463.2007.apm_544.x, 17504299.
50. Otto AM, Muller CS, Huff T, Hannappel E. Chemotherapeutic drugs change actin skeleton organization and the expression of beta-thymosins in human breast cancer cells. Journal of cancer research and clinical oncology 2002, 128(5):247-256. 10.1007/s00432-002-0332-7, 12029440.
51. Klopfleisch R, Schutze M, Gruber AD. RAD51 protein expression is increased in canine mammary carcinomas. Vet Pathol 2010, 47(1):98-101. 10.1177/0300985809353310, 20080488.
52. Klopfleisch R, Klose P, Weise C, Bondzio A, Multhaup G, Einspanier R, Gruber AD. The Proteome of Metastatic Canine Mammary Carcinomas: Similarities and Differences to Human Breast Cancer. J Proteome Res 2010,